Humira is a brand-name drug prescribed to treat rheumatoid arthritis, psoriatic arthritis, and more. It can remain unrefrigerated for up to 14 days, as long as the temperature doesn’t go above 77°F ...

At least one Big Apple resident was among 10 people hospitalized with “severe” illness in the US after injecting Botox bought from unlicensed sources through social media this year, officials said ...

As AbbVie Inc. ABBV looks to plug holes in the sales of its mega-blockbuster arthritis drug Humira, newer immunology drugs will be key to the pharmaceutical giant’s future growth, analysts say. When ...

Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...

Please provide your email address to receive an email when new articles are posted on . Celltrion’s Yuflyma is a high concentration, citrate-free formulation of adalimumab. It is the ninth Humira ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...

(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...

AbbVie delivered Y/Y growth in the second quarter despite Humira’s decline, with Skyrizi and Rinvoq as key growth drivers, achieving 45% and 56% Y/Y growth, respectively. I expect Skyrizi to become a ...

AbbVie did not immediately respond to a request for comment, but has previously said it expects to retain a lower share of the Humira market next year. Pharmacy benefit managers, which act as ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...